Cell Therapeutics buoyed by EU launch of Pixuvri but US plans yet to solidify
This article was originally published in Scrip
Cell Therapeutics began its EU commercial launch of Pixuvri (pixantrone) for the treatment of refractory non-Hodgkin's lymphoma in the Nordic region and will add larger markets later in 2012 and into 2013 as the Seattle, US-based company negotiates pricing with government health programmes.
You may also be interested in...
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.